Harvard Apparatus Regenerative Technology Inc. (HRGN)
OTCMKTS · Delayed Price · Currency is USD
1.572
0.00 (0.00%)
Apr 13, 2026, 9:30 AM EST
Harvard Apparatus Regenerative Technology Employees
Harvard Apparatus Regenerative Technology had 8 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$88,000
Profits / Employee
-$858,625
Market Cap
27.64M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 8 | 0 | - | 8 | 0 |
| Dec 31, 2024 | 8 | -10 | -55.56% | 8 | 0 |
| Dec 31, 2023 | 18 | 10 | 125.00% | 18 | 0 |
| Dec 31, 2022 | 8 | -5 | -38.46% | 7 | 1 |
| Dec 31, 2021 | 13 | 6 | 85.71% | 6 | 7 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HOOKIPA Pharma | 87 |
| Oncotelic Therapeutics | 26 |
| Zeo ScientifiX | 20 |
| Inhibitor Therapeutics | 8 |
| Provectus Biopharmaceuticals | 6 |
| Anebulo Pharmaceuticals | 3 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
Harvard Apparatus Regenerative Technology News
- 2 months ago - Harvard Apparatus Regenerative Technology Collaborates with University of Southern California to Test Treatment for Esophageal Disease - GlobeNewsWire
- 1 year ago - Harvard Apparatus Regenerative Technology Announces Strategic Collaboration with Children's Hospital Capital institute of Pediatrics in Beijing, China to Advance Treatment for Esophageal Atresia - GlobeNewsWire
- 1 year ago - Harvard Apparatus Regenerative Technology Appoints Mao Zhang to Board of Directors - GlobeNewsWire
- 1 year ago - Harvard Apparatus Regenerative Technology Announces $5 Million Financing to Continue Clinical Trial - GlobeNewsWire
- 2 years ago - Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 years ago - Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 years ago - Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy - GlobeNewsWire
- 2 years ago - Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus - GlobeNewsWire